| 4.71 -0.21 (-4.27%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.85  |
1-year : | 6.72 |
| Resists | First : | 5.01 |
Second : | 5.76 |
| Pivot price | 4.34  |
|||
| Supports | First : | 3.8 |
Second : | 3.16 |
| MAs | MA(5) : | 4.59 |
MA(20) : | 4.4 |
| MA(100) : | 5.19 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 87.9 |
D(3) : | 76 |
| RSI | RSI(14): 50.5 |
|||
| 52-week | High : | 12.35 | Low : | 3.78 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RXRX ] has closed below upper band by 17.1%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.89 - 4.91 | 4.91 - 4.94 |
| Low: | 4.61 - 4.64 | 4.64 - 4.66 |
| Close: | 4.67 - 4.71 | 4.71 - 4.76 |
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Fri, 05 Dec 2025
Insider Selling: Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells 220,000 Shares of Stock - MarketBeat
Fri, 05 Dec 2025
Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Thu, 04 Dec 2025
Recursion Pharmaceuticals: Is It the Right Time to Buy? - StocksToTrade
Thu, 04 Dec 2025
Recursion Pharmaceuticals: Is This Just The Beginning? - timothysykes.com
Thu, 04 Dec 2025
A Look At The Fair Value Of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - 富途牛牛
Tue, 02 Dec 2025
Quadrature Capital Ltd Takes Position in Recursion Pharmaceuticals, Inc. $RXRX - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 514 (M) |
| Held by Insiders | 5.0359e+008 (%) |
| Held by Institutions | 3.9 (%) |
| Shares Short | 126,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.4054e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 327.5 % |
| Return on Equity (ttm) | -42.3 % |
| Qtrly Rev. Growth | 4.369e+007 % |
| Gross Profit (p.s.) | -87.18 |
| Sales Per Share | -98.99 |
| EBITDA (p.s.) | -5.47228e+008 |
| Qtrly Earnings Growth | -1.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -441 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.05 |
| Price to Cash Flow | 2.03 |
| Dividend | 0 |
| Forward Dividend | 1.4566e+008 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|